ArticleJournal of gastrointestinal oncology2025

Prognostic and safety analysis of capecitabine monotherapy versus CapeOx (capecitabine plus oxaliplatin) in elderly patients with high-risk stage II and stage III MRD-negative colorectal cancer.

Jiawei Zhai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.